New oral drug for eczema takes first step in human safety trial
NCT ID NCT07698756
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This early-stage study tests the safety and tolerability of an experimental oral drug called HRS-8797 in healthy volunteers aged 18 to 55. Researchers will also measure how the drug behaves in the body and whether food affects its absorption. The goal is to gather essential safety data before testing the drug in people with atopic dermatitis (eczema).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- HRS-8797
- What this could lead to
- If safe and well-tolerated, this could pave the way for a new oral treatment option for atopic dermatitis.
- What could go wrong
- This is an early Phase 1 study in healthy people, not patients. It only tests safety and how the drug moves through the body, not whether it works for the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Hospital of Jilin University
Changchun, Jilin, 130000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new injection calm severe eczema when creams fall short?
- Can a new biologic calm severe eczema?
- Can a daily probiotic soothe colicky babies and calm eczema?
- Can a new injection match an existing eczema treatment?
- Can Real-World data unlock better skin disease care?
- Can a meditation app soothe teen eczema?